David Meek (via Bloomberg/Getty)
David Meek hands in his CEO title at Ipsen, leaping across the Atlantic to run a startup prepping its first US drug launch
In November Ferring spun out its late-stage bladder cancer gene therapy into a new US-based company backed by $570 million. A few weeks later …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
